Inmune Bio, Inc. INMB
We take great care to ensure that the data presented and summarized in this overview for Inmune Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INMB
View all-
Vanguard Group Inc Valley Forge, PA848KShares$2.05 Million0.0% of portfolio
-
Black Rock Inc. New York, NY813KShares$1.97 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE596KShares$1.44 Million45.87% of portfolio
-
Ubs Group Ag449KShares$1.09 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA390KShares$943,6330.0% of portfolio
-
Raymond James Financial Services Advisors, Inc. St. Petersburg, FL369KShares$894,0390.0% of portfolio
-
Raymond James Financial Inc St. Petersburg, FL333KShares$807,0140.0% of portfolio
-
State Street Corp Boston, MA275KShares$666,4480.0% of portfolio
-
Dauntless Investment Group, LLC Commerce Township, MI249KShares$601,4711.02% of portfolio
-
Rhenman & Partners Asset Management Ab Stockholm, V7178KShares$431,4470.05% of portfolio
Latest Institutional Activity in INMB
Top Purchases
Top Sells
About INMB
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Insider Transactions at INMB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2024
|
David J Moss Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+0.77%
|
$50,000
$5.29 P/Share
|
|
Sep 12
2024
|
David J Moss Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
7,690
+0.6%
|
$46,140
$6.38 P/Share
|
|
Sep 12
2024
|
Raymond Joseph Tesi President and CEO |
BUY
Open market or private purchase
|
Direct |
15,380
+0.98%
|
$92,280
$6.38 P/Share
|
|
Jun 25
2024
|
Scott Juda Director |
BUY
Open market or private purchase
|
Indirect |
5,000
+6.53%
|
$35,000
$7.27 P/Share
|
|
Apr 19
2024
|
Mark William Lowdell Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,423
+0.95%
|
$115,384
$8.32 P/Share
|
|
Apr 19
2024
|
David J Moss Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,028
+1.4%
|
$144,224
$8.32 P/Share
|
|
Apr 19
2024
|
Raymond Joseph Tesi President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
18,028
+1.16%
|
$144,224
$8.32 P/Share
|
|
Apr 19
2024
|
Scott Juda Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,603
+30.77%
|
$236,824
$8.32 P/Share
|
|
Nov 10
2023
|
Scott Juda Director |
BUY
Open market or private purchase
|
Indirect |
7,000
+15.91%
|
$42,000
$6.95 P/Share
|
|
Jul 12
2023
|
Timothy J Schroeder Director |
SELL
Open market or private sale
|
Indirect |
10,000
-10.85%
|
$110,000
$11.01 P/Share
|
|
Mar 17
2023
|
David J Moss Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+0.2%
|
$15,000
$6.42 P/Share
|
|
May 27
2022
|
David J Moss Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+0.24%
|
$18,000
$6.79 P/Share
|
|
May 26
2022
|
David J Moss Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
7,700
+0.61%
|
$46,200
$6.27 P/Share
|
|
May 26
2022
|
Raymond Joseph Tesi President and CEO |
BUY
Open market or private purchase
|
Direct |
6,300
+0.41%
|
$37,800
$6.41 P/Share
|
|
Mar 22
2022
|
James Kelly Ganjei Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,793
+50.0%
|
$142,344
$8.43 P/Share
|
|
Mar 22
2022
|
David J Moss Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,793
+1.42%
|
$142,344
$8.43 P/Share
|
|
Mar 22
2022
|
Raymond Joseph Tesi President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
23,724
+1.54%
|
$189,792
$8.43 P/Share
|
|
Mar 22
2022
|
Mark William Lowdell Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,590
+1.55%
|
$188,720
$8.43 P/Share
|
|
Nov 17
2021
|
Scott Juda Director |
BUY
Open market or private purchase
|
Indirect |
2,500
+7.69%
|
$32,500
$13.55 P/Share
|
|
Nov 03
2021
|
Raymond Joseph Tesi President and CEO |
SELL
Open market or private sale
|
Direct |
3,626
-0.24%
|
$72,520
$20.0 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 33.1K shares |
|---|